Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Orchestra BioMed Holdings (OBIO) Profit After Tax (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Profit After Tax for 4 consecutive years, with $6.2 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 138.66% to $6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$52.7 million through Dec 2025, up 13.64% year-over-year, with the annual reading at -$52.7 million for FY2025, 13.64% up from the prior year.
  • Profit After Tax for Q4 2025 was $6.2 million at Orchestra BioMed Holdings, up from -$20.8 million in the prior quarter.
  • The five-year high for Profit After Tax was $6.2 million in Q4 2025, with the low at -$20.8 million in Q3 2025.
  • Average Profit After Tax over 4 years is -$12.3 million, with a median of -$13.1 million recorded in 2023.
  • The sharpest move saw Profit After Tax crashed 90.96% in 2023, then skyrocketed 138.66% in 2025.
  • Over 4 years, Profit After Tax stood at -$9.8 million in 2022, then plummeted by 31.47% to -$12.8 million in 2023, then decreased by 26.03% to -$16.2 million in 2024, then skyrocketed by 138.66% to $6.2 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at $6.2 million, -$20.8 million, and -$19.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.